Reshape Lifesciences Share Price Today
(NASDAQ: RSLS)

Name: Reshape Lifesciences Share Price Today (NASDAQ: RSLS) - Reshape Lifesciences Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Reshape Lifesciences share price is $0.99 & ₹86.10 as on 6 Mar 2025, 2.30 'hrs' IST

$0.99

▲

-0.02

(-1.98%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Reshape Lifesciences share price in Dollar and Rupees. Guide to invest in Reshape Lifesciences stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Reshape Lifesciences, along with analyst recommendations, forecasts, and comprehensive financials.

Reshape Lifesciences share price movements

Today's Low: $0.95
Today's High: $1.02
$0.99
4.04%
Downside
Day's Volatility :6.86%
Upside
2.94%
52 Weeks Low: $0.98
52 Weeks High: $29.00
$0.99
0.98%
Downside
52 Weeks Volatility :96.62%
Upside
96.59%

Reshape Lifesciences (RSLS) Returns

Period	Reshape Lifesciences Inc	Index (Russel 2000)
3 Months	-79.55%	0.0%
6 Months	-88.69%	0.0%
1 Year	-89.12%	0.0%
3 Years	-99.96%	-11.6%

Reshape Lifesciences (RSLS) Key Statistics

in dollars & INR

Previous Close	$1.01
Open	$0.98
Today's High	$1.02
Today's Low	$0.95
Market Capitalization	$3.6M
Today's Volume	$48.1K
52 Week High	$29.0
52 Week Low	$0.95
Revenue TTM	$8.0M
EBITDA	$-9.2M
Earnings Per Share (EPS)	$76.2
PE Ratio	0.07
Profit Margin	-112.11%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-184.59%

How to invest in Reshape Lifesciences Stock (RSLS) from India?

It is very easy for Indian residents to invest directly in Reshape Lifesciences from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Reshape Lifesciences stock in both Indian Rupees (INR) and US Dollars (USD). Search for Reshape Lifesciences or RSLS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Reshape Lifesciences or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Reshape Lifesciences shares which would translate to 0.878 fractional shares of Reshape Lifesciences as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Reshape Lifesciences, in just a few clicks!

Returns in Reshape Lifesciences (RSLS) for Indian investors in Rupees

The Reshape Lifesciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Reshape Lifesciences investment value today

Current value as on today

₹15,631

Returns

₹84,369

(-84.37%)

Returns from Reshape Lifesciences Stock

₹89,332 (-89.33%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Reshape Lifesciences (RSLS)

1140%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Reshape Lifesciences Stock from India on INDmoney has increased by 1140% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Reshape Lifesciences

UBS Group AG
0.53%
Tower Research Capital LLC
0.03%
BlackRock Inc
0.02%

Analyst Recommendation on Reshape Lifesciences

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Reshape Lifesciences(by analysts ranked 0 to 5 stars)

Based on 7 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Reshape Lifesciences Stock (RSLS)

What analysts predicted

Upside of 1.01%

Target:

$1.00

Current:

$0.99

Insights on Reshape Lifesciences Stock (Ticker Symbol: RSLS)

Price Movement
In the last 1 month, RSLS stock has moved down by -69.6%
Increasing Revenue
Revenue is up for the last 3 quarters, 1.94M → 2.29M (in $), with an average increase of 7.7% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -2.19M → -1.58M (in $), with an average increase of 19.2% per quarter
RSLS vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 54.6% return, outperforming this stock by 143.3%
RSLS vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 135.7% return, outperforming this stock by 235.7%
Price to Sales
ForRSLS every $1 of sales, investors are willing to pay $0.0, whereas for Boston Scientific Corp., the investors are paying $9.1 for every $1 of sales.

RSLS Reshape Lifesciences Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$606.7K	↓ 52.86%
Net Income	$-81.2M	↑ 139.97%
Net Profit Margin	-13.4K%	↓ 10748.34%

	FY19	Y/Y Change
Revenue	$15.1M	↑ 2387.02%
Net Income	$-74.2M	↓ 8.56%
Net Profit Margin	-491.8%	↑ 12883.88%

	FY20	Y/Y Change
Revenue	$11.3M	↓ 25.12%
Net Income	$-21.6M	↓ 70.85%
Net Profit Margin	-191.43%	↑ 300.37%

	FY21	Y/Y Change
Revenue	$13.6M	↑ 20.36%
Net Income	$-61.9M	↑ 186.33%
Net Profit Margin	-455.39%	↓ 263.96%

	FY22	Y/Y Change
Revenue	$11.2M	↓ 17.35%
Net Income	$-46.2M	↓ 25.38%
Net Profit Margin	-411.16%	↑ 44.23%

	FY23	Y/Y Change
Revenue	$8.7M	↓ 22.79%
Net Income	$-11.4M	↓ 75.36%
Net Profit Margin	-131.22%	↑ 279.94%

	Q2 FY23	Q/Q Change
Revenue	$2.3M	↓ 27.52%
Net Income	$-3.5M	↓ 78.97%
Net Profit Margin	-154.97%	↑ 379.18%

	Q3 FY23	Q/Q Change
Revenue	$2.2M	↓ 4.39%
Net Income	$-3.5M	↑ 1.17%
Net Profit Margin	-163.99%	↓ 9.02%

	Q4 FY23	Q/Q Change
Revenue	$2.0M	↓ 8.03%
Net Income	$-1.7M	↓ 51.95%
Net Profit Margin	-85.67%	↑ 78.32%

	Q1 FY24	Q/Q Change
Revenue	$1.9M	↓ 1.92%
Net Income	$-2.2M	↑ 29.15%
Net Profit Margin	-112.81%	↓ 27.14%

	Q2 FY24	Q/Q Change
Revenue	$2.0M	↑ 1.08%
Net Income	$-1.6M	↓ 27.27%
Net Profit Margin	-81.17%	↑ 31.64%

	Q3 FY24	Q/Q Change
Revenue	$2.3M	↑ 16.64%
Net Income	$-1.6M	↓ 0.88%
Net Profit Margin	-68.98%	↑ 12.19%

	FY18	Y/Y Change
Profit	$442.4K	↑ 26.13%

	FY19	Y/Y Change
Profit	$9.3M	↑ 2003.25%

	FY20	Y/Y Change
Profit	$6.3M	↓ 32.7%

	FY21	Y/Y Change
Profit	$8.3M	↑ 33.31%

	FY22	Y/Y Change
Profit	$6.8M	↓ 18.52%

	FY23	Y/Y Change
Profit	$5.5M	↓ 18.44%

	Q2 FY23	Q/Q Change
Profit	$1.2M	↓ 25.37%

	Q3 FY23	Q/Q Change
Profit	$1.3M	↑ 7.87%

	Q4 FY23	Q/Q Change
Profit	$1.8M	↑ 43.01%

	Q1 FY24	Q/Q Change
Profit	$1.2M	↓ 36.75%

	Q2 FY24	Q/Q Change
Profit	$1.1M	↓ 2.66%

	Q3 FY24	Q/Q Change
Profit	$1.4M	↑ 26.9%

	FY18	Y/Y Change
Operating Cash Flow	$-27.5M	↑ 11.8%
Investing Cash Flow	$-10.3M	↑ 62.2%
Financing Cash Flow	$33.2M	↓ 12.18%

	FY19	Y/Y Change
Operating Cash Flow	$-14.2M	↓ 48.35%
Investing Cash Flow	$-2.0M	↓ 80.5%
Financing Cash Flow	$13.7M	↓ 58.86%

	FY20	Y/Y Change
Operating Cash Flow	$-8.6M	↓ 39.79%
Investing Cash Flow	$-2.4M	↑ 18.67%
Financing Cash Flow	$11.1M	↓ 18.92%

	FY21	Y/Y Change
Operating Cash Flow	$-15.4M	↑ 79.82%
Investing Cash Flow	$1.9M	↓ 177.62%
Financing Cash Flow	$33.3M	↑ 200.67%

	FY22	Y/Y Change
Operating Cash Flow	$-21.9M	↑ 42.45%
Investing Cash Flow	$-92.0K	↓ 104.96%
Financing Cash Flow	$3.1M	↓ 90.6%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-6.7M	↑ 135.41%
Investing Cash Flow	$-3.0K	↓ 57.14%
Financing Cash Flow	$2.3M	↑ 252.66%

Reshape Lifesciences Technicals Summary

Sell

Neutral

Buy

Reshape Lifesciences is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Reshape Lifesciences (RSLS) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Reshape Lifesciences Inc	-71.55%	-88.69%	-89.12%	-99.96%	-99.99%
Medtronic Plc	2.26%	4.07%	8.74%	-12.76%	0.68%
Edwards Lifesciences Corp.	0.07%	8.12%	-19.19%	-34.12%	12.08%
Boston Scientific Corp.	0.07%	27.33%	53.68%	143.5%	203.93%
Stryker Corporation	-0.63%	8.92%	9.84%	53.87%	125.87%
Abbott Laboratories	7.11%	21.64%	15.28%	15.75%	78.63%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Reshape Lifesciences Inc	0.07	0.07	NA	0.0	-1.85	-0.63	NA	16.48
Medtronic Plc	28.75	28.75	1.87	5.45	0.08	0.05	0.03	38.49
Edwards Lifesciences Corp.	30.5	30.5	5.57	2.45	0.17	0.08	NA	16.99
Boston Scientific Corp.	83.9	83.9	1.85	2.86	0.09	0.05	NA	14.76
Stryker Corporation	50.89	50.89	2.85	13.49	0.15	0.07	0.01	54.1
Abbott Laboratories	18.34	18.34	2.52	5.15	0.31	0.06	0.02	27.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Reshape Lifesciences Inc	Buy	$3.6M	-99.99%	0.07	-112.11%
Medtronic Plc	Buy	$120.9B	0.68%	28.75	12.83%
Edwards Lifesciences Corp.	Buy	$42.0B	12.08%	30.5	76.75%
Boston Scientific Corp.	Buy	$154.8B	203.93%	83.9	11.07%
Stryker Corporation	Buy	$150.7B	125.87%	50.89	13.25%
Abbott Laboratories	Buy	$238.6B	78.63%	18.34	31.95%

About Reshape Lifesciences

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

Organization	Reshape Lifesciences
Employees	29
CEO	Mr. Paul F. Hickey
Industry	Medical Specialties

Management People of Reshape Lifesciences

Name	Title
Mr. Dan W. Gladney	Executive Chair
Mr. Paul F. Hickey	CEO, President & Director
Mr. Thomas Stankovich	Senior VP & CFO
Mr. Al Diaz	Vice President of Operations and R&D
Dr. Dov Gal D.V.M., M.B.A.	VP of Regulatory Clinical Quality & Compliance Officer
Mr. Naqeeb A. Ansari	Senior Vice President of Global Commercial Operations

Important FAQs about investing in RSLS Stock from India :

What is Reshape Lifesciences share price today?

Reshape Lifesciences share price today stands at $0.99, Open: $0.98 ; Previous Close: $1.01 ; High: $1.02 ; Low: $0.95 ; 52 Week High: $29.00 ; 52 Week Low: $0.98.

The stock opens at $0.98, after a previous close of $1.01. The stock reached a daily high of $1.02 and a low of $0.95, with a 52-week high of $29.00 and a 52-week low of $0.98.

Can Indians buy Reshape Lifesciences shares?

Yes, Indians can invest in the Reshape Lifesciences (RSLS) from India.

With INDmoney, you can buy Reshape Lifesciences at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Reshape Lifesciences at zero transaction cost.

How can I buy Reshape Lifesciences shares from India?

It is very easy to buy Reshape Lifesciences from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Reshape Lifesciences (RSLS) be purchased?

Yes, you can buy fractional shares of Reshape Lifesciences with INDmoney app.

What are the documents required to start investing in Reshape Lifesciences stocks?

To start investing in Reshape Lifesciences, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.